Merck Serono Is Hoping It Pays To Plan Ahead With New Phase III Trial For Tecemotide
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Merck Serono will conduct a second Phase III study of lung cancer vaccine tecemotide in patients treated concurrently with chemotherapy and radiation. The START trial, which also dosed patients receiving sequential therapy, failed but the predefined, concurrently treated subgroup showed greater median overall survival compared to placebo.
You may also be interested in...
Deal Watch: Hep C M&A Still Thriving; Plus AstraZeneca/Synairgen, MorphoSys/Merck Serono, ViiV/J&J
Merck beats out bids from AbbVie and Johnson & Johnson for Idenix Pharmaceuticals, gaining possession of three promising HCV drug candidates.
Oncothyreon Looks To Leave Merck KGaA's Shadow With Two Cancer Candidates
While awaiting Phase III data on its partnered cancer vaccine Stimuvax, the Seattle biotech is advancing its own PI3 kinase inhibitor and follow-on vaccine projects.
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”